MorphoSys is one of the world’s leading biotechnology companies
focusing on fully human antibodies. With its proprietary technologies,
MorphoSys is developing not only the next generation of therapeutic
antibodies, but also antibodies for research and diagnostics purposes.
MorphoSys is committed to create significant value for its employees,
shareholders, customers and partners through a sustainable business
strategy balancing short-term and long-term growth potentials.
Proprietary Development and Partnered Discovery
In the Proprietary Development and Partnered Discovery segments,
MorphoSys develops drug candidates for commercial partners as well as
for its own proprietary product portfolio. In this regard, the Company
has been successful in establishing a number of partnerships with
renowned biotechnology and pharmaceutical companies. MorphoSys has also
generated several proprietary therapeutic antibody candidates for future
out-licensing to partners.
AbD Serotec
MorphoSys’s third operating segment, AbD Serotec, delivers antibodies
to the research and diagnostics markets. The unit’s growing penetration
of the diagnostics market positions the Company to benefit from the
burgeoning importance of diagnostics for drug development and use.
